OakLabs GmbH of Berlin / Hennigsdorf at MEDICA 2018 in Düsseldorf -- MEDICA - World Forum for Medicine

OakLabs GmbH

Neuendorfstr. 16b, 16761 Berlin / Hennigsdorf

This company is co-exhibitor of
DiagnostikNet-BB Netzwerk Diagnostik Berlin-Brandenburg e.V.

Hall map

MEDICA 2018 hall map (Hall 3): stand G52

Fairground map

MEDICA 2018 fairground map: Hall 3


Dr. Martina Schad


Dr. Jim Kallarackal

Quantum Physicist

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.02  Molecular biomarkers

Our products

Product category: Molecular biomarkers

Fast Track Biomarker Signatures and Companion Diagnostics

The likelihood of bringing a drug entering Phase 1 to the market differs significantly in the various disease areas, from 26.1 % at the high end for hematology to 5.1% at the low end for oncology with an average of 9.6% for all disease areas. Three out of four failing drug candidates fail due to lack of efficacy or safety.

Realizing an intelligent patient selection strategy as a fundamental component of each clinical trial is guaranteed to maximize the likelihood for approval of a new drug. This can be achieved with the use of biomarkers which help
select patients who would benefit from the treatment
prevent the selection of patients who would suffer from adverse effects
Today, only a tiny percentage of clinical trials include the use of biomarkers. Although such studies rely only on single biomarkers the probability of success is still significantly increased.

OakLabs has gone a step further and moved from single biomarkers to complex biomarker signatures which explain a several times larger proportion of responses and therefore facilitate a reliable identification of responders. Based on our unique EVO algorithm which combines concepts from artificial intelligence and machine learning, our complex biomarker signatures build the basis for a superior improvement of the approval rate to even 68%.

More Less

About us

Company details

OakLabs’ goal is to support scientific companies and institutions with groundbreaking revelations, perhaps most notably in the realm of drug development, companion diagnostics (CDx), support of translational medicine studies and development of IEC 62304 compliant medical device software.

The skilled team of quantum physicists and biochemists at OakLabs has developed a new approach to drug development which replaces single biomarkers with a biomarker signature: Multiple molecules are combined in a mathematical model. This enables a new era of reliability in accurately predicting (non-)responders for specific drugs, thus enabling a precision medicine approach. Not only does this lead to success in clinical trials, it can also help to gain market shares in a competitive environment, offering tangible results for continued market success after approval.

OakLabs was founded in 2011 by Martina Schad, Ph.D., and Jim
Kallarackal, Ph.D. Currently, the company has offices in Hennigsdorf/Berlin, Germany and Boston, USA.

More Less

Company data



Area of business